IDx & MDx platform
In this technical paper, BioLizard presents its end-to-end solution for biomarker discovery and development: our so called BioLizard IDx & MDx platform. The IDx platform is our in-house established, fast and accurate platform that supports bioinformatic scientists throughout the whole process of biomarker discovery. Furthermore, it allows them to be more productive by automating repetitive tasks. The platform takes uses raw data from sequencing or microarray experiments as well as clinical metadata.
On the other hand, the MDx platform is comprised of a range of software tools which we make use of in the clinical validation phase of a given biomarker panel, thus accelerating an independent validation study.
The process of biomarker discovery and its development can be spilt up in to 4 sequential parts.
Scoping & discovery: in combination with clinical data, the raw outcome that is generated on the sequencing platform is the only input BioLizard needs in order to start the biomarker discovery process.
Biomarker discovery: identifying the most informative biomarkers differentiating between two or more phenotypes is challenging due to the fact that the number of possible biomarkers is much higher than the number of available samples. Therefore, there is a need to do dimensionality reduction.
Algorithm development: leveraging multiple candidate biomarker signatures generated in the previous step by building different machine learning models and assessing their performance in different experiments.
Signature validation: the final stage in the development of a biomarker panel is the assessment of its clinical validity and utility. In order to properly validate the final model, a distinction is made between internal and external validation.
It is clear that the development of omics-based biomarker signatures is often not a straightforward, single-step process and many companies may struggle to navigate through the challenges successfully. Based on long-track experience, BioLizard has developed a tailor-made platform for either identification and discovery of biomarkers (IDx platform) or independent validation of an already developed biomarker signature (MDx platform).